Leptin’s Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals
Leptin is an adipocyte-secreted hormone that has been proposed to regulate energy homeostasis as well as meta- bolic, reproductive, neuroendocrine, and immune functions. In the context of open-label uncontrolled studies, leptin administration has demonstrated insulin-sensitizing effects in patients with congenital lipodystrophy associated with relative leptin deficiency. Leptin administration has also been shown to decrease central fat mass and improve insulin sensitivity and fasting insulin and glucose levels in HIV-infected patients with highly active antiretroviral therapy (HAART)-induced lipodystrophy, insulin resistance, and leptin deficiency. On the contrary, the effects of leptin treatment in leptin-replete or hyperleptinemic obese individuals with glucose intolerance and diabetes mel- litus have been minimal or null, presumably due to leptin tolerance or resistance that impairs leptin action. Similarly, experimental evidence suggests a null or a possibly adverse role of leptin treatment in nonlipodystrophic patients with nonalcoholic fatty liver disease. In this review, we present a description of leptin biology and signaling; we summarize leptin’s contribution to glucose metabolism in animals and humans in vitro, ex vivo, and in vivo; and we provide insights into the emerging clinical applications and therapeutic uses of leptin in humans with lipodystrophy and/or diabetes. (Endocrine Reviews 34: 377– 412, 2013)
Leptin is an adipocyte-secreted hormone that has been proposed to regulate energy homeostasis as well as meta- bolic, reproductive, neuroendocrine, and immune functions. In the context of open-label uncontrolled studies, leptin administration has demonstrated insulin-sensitizing effects in patients with congenital lipodystrophy associated with relative leptin deficiency. Leptin administration has also been shown to decrease central fat mass and improve insulin sensitivity and fasting insulin and glucose levels in HIV-infected patients with highly active antiretroviral therapy (HAART)-induced lipodystrophy, insulin resistance, and leptin deficiency. On the contrary, the effects of leptin treatment in leptin-replete or hyperleptinemic obese individuals with glucose intolerance and diabetes mel- litus have been minimal or null, presumably due to leptin tolerance or resistance that impairs leptin action. Similarly, experimental evidence suggests a null or a possibly adverse role of leptin treatment in nonlipodystrophic patients with nonalcoholic fatty liver disease. In this review, we present a description of leptin biology and signaling; we summarize leptin’s contribution to glucose metabolism in animals and humans in vitro, ex vivo, and in vivo; and we provide insights into the emerging clinical applications and therapeutic uses of leptin in humans with lipodystrophy and/or diabetes. (Endocrine Reviews 34: 377– 412, 2013)
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
doi: 10.1210/er.2012-1053 edrv.endojournals.org 409
of leptin replacement therapy. Arq Bras Endocrinol
Metab. 2010;54:690–697.
195. Fatima W, Shahid A, Imran M, et al. Leptin deficiency and
leptin gene mutations in obese children from Pakistan. Int
J Pediatr Obes. 2011;419–427.
196. Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A
leptin missense mutation associated with hypogonadism
and morbid obesity. Nat Genet. 1998;18:213–215.
197. Mantzoros CS, Ozata M, Negrao AB, et al. Synchronicity
of frequently sampled thyrotropin (TSH) and leptin concentrations
in healthy adults and leptin-deficient subjects:
evidence for possible partial TSH regulation by leptin in
humans. J Clin Endocrinol Metab. 2001;86:3284–3291.
198. Andreev VP, Paz-Filho G, Wong ML, Licinio J. Deconvolution
of insulin secretion, insulin hepatic extraction posthepatic
delivery rates and sensitivity during 24-hour standardized
meals: time course of glucose homeostasis in
leptin replacement treatment. Horm Metab Res. 2009;41:
142–151.
199. Clément K, Vaisse C, Lahlou N, et al. A mutation in the
human leptin receptor gene causes obesity and pituitary
dysfunction. Nature. 1998;392:398–401.
200. Farooqi IS, Wangensteen T, Collins S, et al. Clinical and
molecular genetic spectrum of congenital deficiency of the
leptin receptor. N Engl J Med. 2007;356:237–247.
201. Hunt CE, Lindsey JR, Walkley SU. Animal models of diabetes
and obesity, including the PBB/Ld mouse. Fed Proc.
1976;35:1206–1217.
202. Haluzik M, Colombo C, Gavrilova O, et al. Genetic background
(C57BL/6J versus FVB/N) strongly influences the
severity of diabetes and insulin resistance in ob/ob mice.
Endocrinology. 2004;145:3258–3264.
203. Mantzoros CS. W(h)ither metreleptin for lipodystrophy
and the metabolic syndrome? Endocr Pract. 2010;29:
1–18.
204. Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy:
pathophysiology and advances in treatment. Nat Rev Endocrinol.
2011;7:137–150.
205. Garg A, Agarwal AK. Lipodystrophies: disorders of adipose
tissue biology. Biochim Biophys Acta. 2009;1791:
507–513.
206. Reue K, Péterfy M. Mouse models of lipodystrophy. Curr
Atheroscler Rep. 2000;2:390–396.
207. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein
JL. Leptin reverses insulin resistance and diabetes
mellitus in mice with congenital lipodystrophy. Nature.
1999;401:73–76.
208. Asilmaz E, Cohen P, Miyazaki M, et al. Site and mechanism
of leptin action in a rodent form of congenital lipodystrophy.
J Clin Invest. 2004;113:414–424.
209. Gavrilova O, Marcus-Samuels B, Leon LR, Vinson C, Reitman
ML. Leptin and diabetes in lipoatrophic mice. Nature.
2000;403:850.
210. Ebihara K, Ogawa Y, Masuzaki H. Transgenic overexpression
of leptin rescues insulin resistance and diabetes in
a mouse model of lipoatrophic diabetes. Diabetes. 2001;
50:1440–1448.
211. Chan JL, Oral EA. Clinical classification and treatment of
congenital and acquired lipodystrophy. Endocr Pract.
2010;16:310–323.
212. Vadacca M, Margiotta DP, Navarini L, Afeltra A. Leptin
in immuno-rheumatological diseases. Cell Mol Immunol.
2011;8:203–212.
213. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy
for lipodystrophy. N Engl J Med. 2002;346:570–578.
214. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin
resistance and hepatic steatosis in patients with severe
lipodystrophy. J Clin Invest. 2002;109:1345–1350.
215. Ebihara K, Masuzaki H, Nakao K. Long-term leptin-replacement
therapy for lipoatrophic diabetes.NEngl J Med.
2004;351:615–616.
216. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM,
Gorden P. Long-term efficacy of leptin replacement in patients
with generalized lipodystrophy. Diabetes. 2005;54:
1994–2002.
217. Matarese G, Sanna V, Lechler RI, et al. Leptin accelerates
autoimmune diabetes in female NOD mice. Diabetes.
2002;51:1356–1361.
218. Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of
leptin therapy in the different forms of human lipodystrophy.
Diabetologia. 2010;53:27–35.
219. Ebihara K, Kusakabe T, Hirata M, et al. Efficacy and safety
of leptin-replacement therapy and possible mechanisms of
leptin actions in patients with generalized lipodystrophy.
J Clin Endocrinol Metab. 2007;92:532–541.
220. Oral EA, Chan JL. Rationale for leptin-replacement therapy
for severe lipodystrophy. Endocr Pract. 2010;16:324–
333.
221. Chan JL, Lutz K, Cochran E, et al. Clinical effects of longterm
metreleptin treatment in patients with lipodystrophy.
Endocr Pract. 2011;17:922–932.
222. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum
adiponectin and leptin levels in patients with lipodystrophies.
J Clin Endocrinol Metab. 2002;87:2395.
223. Simha V, Subramanyam L, Szczepaniak L, et al. Comparison
of efficacy and safety of leptin replacement therapy in
moderately and severely hypoleptinemic patients with familial
partial lipodystrophy of the Dunnigan variety. J Clin
Endocrinol Metab. 2012;97:785–792.
224. Leow MK, Addy CL, Mantzoros CS. Human immunodeficiency
virus/highly active antiretroviral therapy-associated
metabolic syndrome: clinical presentation, pathophysiology,
and therapeutic strategies. J Clin Endocrinol
Metab. 2003;88:1961–1976.
225. Jacobson DL, Knox T, Spiegelman D, Skinner S, Gorbach
S, Wanke C. Prevalence of, evolution of, and risk factors
for fat atrophy and fat deposition in a cohort of
HIV-infected men and women. Clin Infect Dis. 2005;40:
1837–1845.
226. Magkos F, Mantzoros CS. Body fat redistribution and metabolic
abnormalities in HIV-infected patients on highly
active antiretroviral therapy: novel insights into pathophysiology
and emerging opportunities for treatment.
Metab Clin Exp. 2011;60:749–753.
227. Power R, Tate H, McGill S, Taylor C. A qualitative study
of the psychosocial implications of lipodystrophy syndrome
on HIV positive individuals. Sex Transm Infect.
2003;79:137–141.
228. Grinspoon S, Carr A. Cardiovascular risk and body-fat
abnormalities in HIV-infected adults. N Engl J Med. 2005;
352:448–462.
229. Brennan AM, Lee JH, Tsiodras S, et al. r-metHuLeptin
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 10 June 2014. at 01:44 For personal use only. No other uses without permission. . All rights reserved.
Change language